DoxorubicinAntibiotics, AntineoplasticDose-Response Relationship, DrugAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantRadiation DosageRadiation, IonizingRadiation InjuriesAntineoplastic AgentsCombined Modality TherapyCyclophosphamideDose-Response Relationship, RadiationCisplatinTreatment OutcomeRadiation ToleranceRadiationRadiation MonitoringBreast NeoplasmsRadiation ProtectionDrug Administration ScheduleEtoposideDisease-Free SurvivalSurvival AnalysisDrug Resistance, NeoplasmPaclitaxelNeoadjuvant TherapyNeoplasm StagingVinblastineRadiotherapySurvival RateRadiotherapy DosageMethotrexatePrognosisNeoplasmsRadiation OncologyLung NeoplasmsRazoxaneTime FactorsVincristineIfosfamideCell Line, TumorBleomycinNeoplasm Recurrence, LocalTaxoidsCarboplatinAnthracyclinesRadiation Injuries, ExperimentalRadiation PneumonitisCosmic RadiationRadiometryGamma RaysRadiotherapy, AdjuvantNeoplasms, Radiation-InducedFollow-Up StudiesP-GlycoproteinDeoxycytidineAntineoplastic Agents, PhytogenicInfusions, IntravenousApoptosisDaunorubicinAdenocarcinomaAntineoplastic Agents, AlkylatingOvarian NeoplasmsCell SurvivalNeoplasm MetastasisDrug CarriersSarcomaHodgkin DiseaseLymphoma, Non-HodgkinAntimetabolites, AntineoplasticInduction ChemotherapyNeutropeniaDose FractionationDrug Resistance, MultipleDacarbazineBackground RadiationBrain NeoplasmsLiposomesSalvage TherapyNauseaCytarabineMitoxantroneBone NeoplasmsOrganoplatinum CompoundsOsteosarcomaVomitingTumor Cells, CulturedRadiation-Sensitizing AgentsProspective StudiesCarcinoma, Non-Small-Cell LungLeukopeniaDrug SynergismUltraviolet RaysChemotherapy, Cancer, Regional PerfusionClinical Trials as TopicGranulocyte Colony-Stimulating FactorDNA DamageRadiation-Protective AgentsPolyethylene GlycolsRadiation Effects